The DOI matches its Crossref record.
Sleep Latency Is Shortened During 4 Weeks of Treatment With Zaleplon, a Novel Nonbenzodiazepine Hypnotic
Abstract
BACKGROUND: Zaleplon is a short-acting pyrazolopyrimidine hypnotic with a rapid onset of action. This multicenter study compared the efficacy and safety of 3 doses of zaleplon with those of placebo in outpatients with DSM-III-R insomnia. Zolpidem, 10 mg, was used as an active comparator. METHOD: After a 7-night placebo (baseline) period, 615 adult patients were randomly assigned to receive, in double-blind fashion, I of 5 treatments (zaleplon, 5, 10, or 20 mg; zolpidem, 10 mg; or placebo) for 28 nights, followed by placebo treatment for 3 nights. Sleep latency, sleep maintenance, and sleep quality were determined from sleep questionnaires that patients completed each morning. The occurrence of rebound insomnia and withdrawal effects on discontinuation of treatment was also assessed. All levels of significance were p < or = .05. RESULTS: Median sleep latency was significantly lower with zaleplon, 10 and 20 mg, than with placebo during all 4 weeks of treatment and with zaleplon, 5 mg, for the first 3 weeks. Zaleplon, 20 mg, also significantly increased sleep duration compared with placebo in all but week 3 of the study. There was no evidence of rebound insomnia or withdrawal symptoms after discontinuation of 4 weeks of zaleplon treatment. Zolpidem, 10 mg, significantly decreased sleep latency, increased sleep duration, and improved sleep quality at most timepoints compared with placebo; however, after discontinuation of zolpidem treatment, the incidence of withdrawal symptoms was significantly greater than that with placebo and there was an indication of significant rebound insomnia for some patients in the zolpidem group compared with those in the placebo group. The frequency of adverse events in the active treatment groups did not differ significantly from that in the placebo group. CONCLUSION: Zaleplon is effective in the treatment of insomnia. In addition, zaleplon appears to provide a favorable safety profile, as indicated by the absence of rebound insomnia and withdrawal symptoms once treatment was discontinued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia
ERMAN, M., SEIDEN, D., ZAMMIT, G., SAINATI, S., & ZHANG, J. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2005.09.004 · Cited by 434
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Fatigue Countermeasures in Aviation
Caldwell, J. A., Mallis, M. M., Caldwell, J. L., Paul, M. A., Miller, J. C., & Neri, D. F. (2009) · Aviation, Space, and Environmental Medicine · doi:10.3357/asem.2435.2009 · Cited by 295
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294
Zaleplon: A Review of its Use in the Treatment of Insomnia
Dooley, M., & Plosker, G. L. (2000) · Drugs · doi:10.2165/00003495-200060020-00014 · Cited by 287
Wilt, T. J., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., Khawaja, I. S., Diem, S., Koffel, E., Ouellette, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1781 · Cited by 275
The assessment and management of insomnia: an update
Krystal, A. D., Prather, A. A., & Ashbrook, L. H. (2019) · World Psychiatry · doi:10.1002/wps.20674 · Cited by 256
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
Long-term use of sedative hypnotics in older patients with insomnia
Ancoli-Israel, S., Richardson, G. S., Mangano, R. M., Jenkins, L., Hall, P., & Jones, W. S. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2004.10.015 · Cited by 154
“Although safety and efficacy have been established for these agents when used for short-duration therapy both in the younger [9–13] and older population [14], there are few data that establish their continued efficacy and safety in long-term use.”
BackgroundComparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98
Insomnia in women: an overlooked epidemic?
Soares, C. N. (2005) · Archives of Women's Mental Health · doi:10.1007/s00737-005-0100-1 · Cited by 89
Meta-Analyses of Hypnotics and Infections: Eszopiclone, Ramelteon, Zaleplon, and Zolpidem
Joya, F. L., Kripke, D. F., Loving, R. T., Dawson, A., & Kline, L. E. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27552 · Cited by 62
Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
Barbera, J., & Shapiro, C. (2005) · Drug Safety · doi:10.2165/00002018-200528040-00003 · Cited by 51
Metadata
- Authors
- Elie, R., Ruther, E., Farr, I., Emilien, G., Salinas, E., & The Zaleplon Clinical Study Group
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1999-08-15
- Volume
- 60
- Issue
- 8
- Pages
- 536-544
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2082704567
- Cited by
- 191
- References
- 0
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.